8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549



                                    FORM 8-K
                                 CURRENT REPORT



     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



       Date of Report (Date of earliest event reported) November 14, 2003



                        Progenics Pharmaceuticals, Inc.
                        -------------------------------
             (Exact name of registrant as specified in its charter)



          Delaware                  000-23143                   13-3379479
          --------                  ----------                  ----------
(State or other jurisdiction        (Commission              (IRS Employer
     of incorporation)              File Number)          Identification No.)



             777 Old Saw Mill River Road, Tarrytown, New York      10591
             -----------------------------------------------------------
               (Address of principal executive offices)         (Zip Code)


        Registrant's telephone number, including area code (914) 789-2800
                                                            -------------


         --------------------------------------------------------------
         (Former name or former address, if changed since last report.)







Item 7.  Financial Statements and Exhibits.

(c) Exhibits

       EXHIBIT NUMBER         DESCRIPTION

       Exhibit 99.1           Press Release dated November 14, 2003 (filed
                              herewith).


Item 9. Regulation FD Disclosure.

         On November 14, 2003, Progenics Pharmaceuticals, Inc. (the "Company")
issued a press release announcing the pricing of its public offering of 3.25
million share of its common stock at a price of $16.25 per share. Net proceeds
to the Company after expenses are expected to be approximately $48.9 million.
The Company has also granted an option to the underwriters to purchase an
additional 487,500 shares of common stock. A copy of the press release is
attached as Exhibit 99.1.

         The information furnished pursuant to Item 9 in this Form 8-K shall not
be deemed to be "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liabilities of that Section,
unless we specifically incorporate it by reference in a document filed under the
Securities Act of 1933 or the Securities Exchange Act of 1934. We undertake no
duty or obligation to publicly update or revise the information furnished
pursuant to Item 9 in this Form 8-K.







                                   SIGNATURES

                  Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                          PROGENICS PHARMACEUTICALS, INC.


                          By:  /s/ PHILIP K. YACHMETZ
                               -----------------------
                                   Philip K. Yachmetz
                                   Vice President, General Counsel and Secretary


Date:  November 14, 2003
       -----------------

EX-99

                                                                   Exhibit 99.1

Progenics Prices 3.25 Million Common Shares in $52.8 Million Follow-on
Offering

    TARRYTOWN, N.Y.--(BUSINESS WIRE)--Nov. 14, 2003--Progenics
Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the pricing of
its public offering of 3.25 million shares of its common stock at a
price of $16.25 per share. Net proceeds to the Company after expenses
are expected to be approximately $48.9 million. The Company has also
granted an option to the underwriters to purchase an additional
487,500 shares of common stock. The Company intends to use the
proceeds from the offering for working capital and general corporate
purposes, including, without limitation, the funding of clinical
trials of product candidates, expansion of its manufacturing
facilities and research and development projects.
    The underwriters for this offering include joint-lead managers
Citigroup and CIBC World Markets Corp. and co-managers Lazard; Legg
Mason Wood Walker, Incorporated; and Punk, Ziegel & Company.
    A registration statement relating to these securities was filed
with and has been declared effective by the U.S. Securities and
Exchange Commission. This press release does not constitute an offer
to sell or the solicitation of an offer to buy any of the securities
of Progenics, and there shall be no sale of these securities in any
state or jurisdiction in which such an offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
    This offering of the shares of common stock may be made only by
means of a prospectus, copies of which can be obtained from Citigroup,
388 Greenwich Street, New York, New York 10013; CIBC World Markets
Corp., 417 Fifth Avenue, New York, New York 10016; Lazard, 30
Rockefeller Plaza, New York, New York 10020; Legg Mason Wood Walker,
Incorporated, 100 Light Street, Baltimore, Maryland 21202; or Punk,
Ziegel & Company, 520 Madison Avenue, New York, New York 10022.

    CONTACT: Progenics Pharmaceuticals, Inc.
             Richard W. Krawiec, Ph.D., 914-789-2800
             rkrawiec@progenics.com